Rachana Bhoite, Shobana Shanmugam, Lalithya Pratti Varalakshmi, Sudha Vasudevan, Vinita Satyavrat, Gayathri Rajagopal, Kalpana Natarajan, Ranjit Mohan Anjana, Viswanathan Mohan
Dr. Reddy's Laboratories Pvt Ltd. Hyderabad Telangana India.
Department of Foods Nutrition & Dietetics Research, Madras Diabetes Research Foundation Chennai Tamil Nadu India.
Food Sci Nutr. 2023 Aug 3;11(9):5379-5387. doi: 10.1002/fsn3.3495. eCollection 2023 Sep.
The study was carried out to measure the glycemic index (GI) of an oral food supplement for people with CKD as well as on patients on maintenance dialysis. The study was conducted as per international protocols for testing GI, was approved by the local institutional ethics committee, and was registered with the Clinical Trial Registry of India (CTRI). This was a crossover randomized controlled study which enrolled 15 participants between the ages of 18 and 45 years. The participants were randomly allotted to one group that consumed either the reference food (27.5 g of glucose monohydrate) or 118 g of the nutritional supplement which contained 25 g of available carbohydrates. Fasting capillary blood samples as well as blood samples at different time intervals as per the GI protocol, after consumption of either the supplement or the reference food were taken from the participants. Each testing day was separated by a 3-day washout period. GI was calculated from the incremental area under the blood glucose response elicited by the nutritional supplement as a percentage of the response after the consumption of 25 g of glucose (27.5 g of glucose monohydrate) by the same participant using a standard formula. The GI of the nutritional supplement was calculated to be 10.3 ± 2.0 which is considered to be low as per international GI testing standards. The product was created to supplement the diet of people with CKD at different stages and to help prevent the progression from CKD to ESRD as well as the risk for CVD. This product was found to have a low GI which is desirable for people with CKD as well as diabetics in general who are at risk for developing CKD.
本研究旨在测量一种针对慢性肾脏病(CKD)患者以及维持性透析患者的口服食品补充剂的血糖生成指数(GI)。该研究按照国际GI测试方案进行,获得了当地机构伦理委员会的批准,并在印度临床试验注册中心(CTRI)进行了注册。这是一项交叉随机对照研究,纳入了15名年龄在18至45岁之间的参与者。参与者被随机分为一组,分别食用参考食物(27.5克一水葡萄糖)或118克含有25克可利用碳水化合物的营养补充剂。在参与者食用补充剂或参考食物后,按照GI方案在不同时间间隔采集空腹毛细血管血样以及血样。每个测试日之间间隔3天的洗脱期。使用标准公式,根据营养补充剂引起的血糖反应增量面积占同一参与者食用25克葡萄糖(27.5克一水葡萄糖)后反应的百分比来计算GI。根据国际GI测试标准,该营养补充剂的GI计算值为10.3±2.0,被认为较低。该产品旨在补充不同阶段CKD患者的饮食,并有助于预防CKD进展为终末期肾病(ESRD)以及心血管疾病(CVD)风险。发现该产品的GI较低,这对于CKD患者以及一般有发展为CKD风险的糖尿病患者来说是理想的。